Carcinoma, Transitional Cell – Talk Bio

Actionable Insights Powered by AI

Tyra Biosciences Unveils Early Data for FGFR3 Inhibitor, TYRA-300, in Challenge to J&J’s Balversa

6 months ago talkbio0Tagged Balversa, Carcinoma, Transitional Cell, concerns, Effectiveness, FGFR3 protein, human, Inhibitor, J&J, Malignant neoplasm of urinary bladder, Safety, Tyra Biosciences, TYRA-300

Tyra Biosciences, TYRA-300, Balversa, J&J, bladder cancer, urothelial carcinoma, FGFR3 inhibitor, safety concerns, efficacy data

Gilead Withdraws Trodelvy for Bladder Cancer in US After Confirmatory Trial Failure

6 months ago talkbio0Tagged Accelerated, Approved, Carcinoma, Transitional Cell, Gilead Sciences, Malignant neoplasm of urinary bladder, Trodelvy, United States Food and Drug Administration

Gilead Sciences, Trodelvy, bladder cancer, urothelial carcinoma, FDA, accelerated approval, drug withdrawal

Johnson & Johnson Presents Updated Findings on Balversa Treatment for Bladder Cancer

12 months ago talkbio0Tagged Balversa, Carcinoma, Transitional Cell, Clinical Data, Fibroblast Growth Factor Receptors, Inhibitor, Johnson and Johnson, Malignant neoplasm of urinary bladder

Johnson & Johnson, Balversa, bladder cancer, clinical data, FGFR inhibitor, targeted therapy, urothelial carcinoma.